This blog was written by Mark Manfredi, CEO of Kyn Therapeutics and former Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC.  Last week we learned about the failure of the much anticipated ECHO-301/KEYNOTE-252 trial that studied

Recently there’s been talk of a caravan of immigrants marching towards the United States, principally focused on Mexico and Central America.  But there’s also another caravan, this one at work in the biopharma business: the long term migration of science

Like all avid fly fishermen, I can recount many stories about the big ones that got away. The same goes for my experience in venture capital… as I’ve certainly missed some big ones. With the acquisition of Juno Therapeutics by

This blog was written by Samantha Truex, an Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. People who know me well will agree that patience is not one of my personal virtues.  That said, I recognize

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC.   The biotech twittersphere recently engaged in very thoughtful debate (resulting in a great piece by

This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC. It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and

Today we recognize and celebrate #RareDiseaseDay to raise awareness of rare diseases and their impact on patients’ lives. Nearly 1 out of 10 Americans lives with a rare disease – more than 30M people in the United States.  NORD has documented over

Biotech venture investors often prefer to back executives and entrepreneurs with a bit of grey hair. Seasoned industry veterans that possess leadership charisma along with years of experience, and the oft-accompanying learned judgement, are highly sought-after in biopharma’s seemingly endless

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. Two years ago, Bloomberg Business published a feature entitled At Biotech Party, Gender Diversity Means Cocktail Waitresses. Within three

My experience as an adaptive ski coach has been nothing short of life-changing. I don’t say that with hyperbole. By bringing together my passion for the mountains with my profession as an investor in biomedical therapies, adaptive coaching completes the

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In 2015 I went to both the JPMorgan and CES conferences, back to back, and attended numerous can’t-miss dinners,

This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC.   It seems so clear now: gene therapy is on a roll.  As 2017 came to a close, the